Zealand Pharma A-S
Closed
322.6 -5.26
Overview
Share price change
24h
Min
322.3
Max
338.1
Income | -15M -394M |
|---|---|
Sales | -35M 34M |
P/E Sector Avg | 3.648 57.002 |
EPS | -5.58 |
Profit margin | -1,158.824 |
Employees | 544 |
EBITDA | 124M -379M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +25.15% upside |
Next Earnings | 12 lis 2026 |
|---|
Market Cap | 1.2B 22B |
|---|---|
Previous open | 327.86 |
Previous close | 322.6 |
Zealand Pharma A-S Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Zealand Pharma A-S Forecast
Price Target
By TipRanks
25.15% upside
12 Months Forecast
Average 270.582 DKK 25.15%
High 270.568 DKK
Low 270.568 DKK
Based on 1 Wall Street analysts offering 12 month price targets forZealand Pharma A-S - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Zealand Pharma A-S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
